Grifols GRFS
NASDAQ GRFS
$8.00 +0.01 (+0.13%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grifols (GRFS) Long-Term Investments (2009 - 2025)

Grifols' (GRFS) quarterly Long-Term Investments came in at $112.9 million in Q4 2025, up 53.14% YoY from $73.7 million in Q4 2024, and up 53.14% on a QoQ basis from $73.7 million in Q4 2024.

Grifols (GRFS) Long-Term Investments (2009 - 2025) Analysis & Trends

Grifols (GRFS) has 17 years of Long-Term Investments data on file, last reported at $112.9 million in Q4 2025.

  • Quarterly Long-Term Investments rose 53.14% year-over-year to $112.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $112.9 million (up 53.14% YoY) and the FY2025 annual result came in at $112.9 million, up 1781.87% from the prior year.
  • Long-Term Investments climbed to $112.9 million in Q4 2025, from $73.7 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $1.8 billion in Q4 2021 to a low of $73.7 million in Q4 2024.
  • A 5-year average of $786.5 million and a median of $453.0 million in 2023 frame the typical range for Long-Term Investments.
  • Annual changes were most pronounced in 2021 — Long-Term Investments soared 423.86% — and 2024, when it tumbled 83.72%.
  • Tracing GRFS's Long-Term Investments over 5 years: stood at $1.8 billion in 2021, then retreated by 13.39% to $1.5 billion in 2022, then slumped by 70.36% to $453.0 million in 2023, then plunged by 83.72% to $73.7 million in 2024, then soared by 53.14% to $112.9 million in 2025.
  • The last three Long-Term Investments figures came in at $112.9 million (Q4 2025), $73.7 million (Q4 2024), and $453.0 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 266.00 Mn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn 1.22 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn 69.00 Mn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 297.00 Mn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 1.56 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 135.51 Mn
10 Grifols 5.45 Bn 4.45 Bn - 112.91 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 112.91 Mn
Dec 31, 2024 73.73 Mn
Dec 31, 2023 452.97 Mn
Dec 31, 2022 1.53 Bn
Dec 31, 2021 1.76 Bn
Dec 31, 2020 -544.88 Mn
Sep 30, 2020 194.29 Mn
Mar 31, 2020 504.50 Mn
Dec 31, 2019 126.71 Mn
Sep 30, 2019 156.09 Mn
Mar 31, 2019 147.46 Mn
Dec 31, 2018 258.99 Mn
Sep 30, 2018 15.48 Mn
Jun 30, 2018 45.28 Mn
Mar 31, 2018 134.15 Mn
Dec 31, 2017 257.87 Mn
Jun 30, 2017 22.56 Mn
Dec 31, 2016 4.05 Mn
Sep 30, 2016 100.76 Mn
Jun 30, 2016 98.35 Mn